5,6-Dihydroxy-8-Aminoquinoline

5,6-Dihydroxy-8-Aminoquinoline

SCHEMBL5640903

Nc1cc(O)c(O)c2cccnc12

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 7/20 0.61
HSP90AB1 P08238 2/20 0.61
IDO1 P14902 3/20 0.58
PSMB5 P28074 1/20 0.58
MMP14 P50281 3/20 0.56
KDM4E B2RXH2 10/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
MPI P34949 1/20 0.49
CASP6 P55212 2/20 0.47
NSD2 O96028 1/20 0.47
G6PD P11413 1/20 0.47
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
HTT P42858 6/20 0.47
ALDH1A1 P00352 6/20 0.47
LMNA P02545 6/20 0.47
MAPT P10636 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
TDP1 Q9NUW8 5/20 0.47
TP53 P04637 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9308262 0.87 HSP90AA1 (0.73) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL8626641 0.85 HSP90AA1 (0.58) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL12192928 0.78 NSD2 (0.68) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL1133269 0.77 HSP90AA1 (0.72) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL687239 0.75 HSP90AA1 (0.58) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL4457883 0.75 HSP90AA1 (0.72) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL15339705 0.75 PIK3CD (0.58) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL18455869 0.75 HSP90AA1 (0.56) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL11973547 0.74 MEN1 (0.51) HSP90AA1HSP90AB1IDO1PSMB5MMP14
SCHEMBL688655 0.73 HSP90AA1 (1.00) HSP90AA1HSP90AB1IDO1PSMB5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9028562-B2 Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor L'OREAL (FR) 2015-05-12 US disclosed
US-9028562-B2 Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor L'OREAL (FR) 2015-05-12 US disclosed
US-20140041133-A1 DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR L'OREAL (FR) 2014-02-13 US disclosed
US-20140041133-A1 DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR L'OREAL (FR) 2014-02-13 US disclosed
US-7183291-B2 Method for the treatment of malaria by the use of primaquine derivative N1-(3-ethylidinotetrahydrofuran-2-one)-N4- (6-methoxy-8-quinolinyl)-1,4-pentanediamine as gametocytocidal agent COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-02-27 US disclosed
US-7183291-B2 Method for the treatment of malaria by the use of primaquine derivative N1-(3-ethylidinotetrahydrofuran-2-one)-N4- (6-methoxy-8-quinolinyl)-1,4-pentanediamine as gametocytocidal agent COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-02-27 US disclosed
US-7183291-B2 Method for the treatment of malaria by the use of primaquine derivative N1-(3-ethylidinotetrahydrofuran-2-one)-N4- (6-methoxy-8-quinolinyl)-1,4-pentanediamine as gametocytocidal agent COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-02-27 US disclosed
EP-1055427-B1 Use of primaquine derivatives for the treatment of malaria COUNCIL SCIENT IND RES (IN) 2004-10-13 EP disclosed
US-20030199697-A1 METHOD FOR THE TREATMENT OF MALARIA BY THE USE OF PRIMAQUINE DERIVATIVE N1-(3-ETHYLIDINOTETRAHYDROFURAN-2-ONE) -N 4-(6-METHOXY-8-QUINOLINYL)-1,4-PENTANEDIAMINE AS GAMETOCYTOCIDAL AGENT COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-10-23 US disclosed
EP-1055427-A1 Use of primaquine derivatives for the treatment of malaria Council of Scientific and Industrial Research (IN) 2000-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140041133-A1 DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR HADHB, HADH, FABP4 HSP90AA1 2612/4885HSP90AB1 2459/4885IDO1 1046/4885
US-20030199697-A1 METHOD FOR THE TREATMENT OF MALARIA BY THE USE OF PRIMAQUINE DERIVATIVE N1-(3-ETHYLIDINOTETRAHYDROFURAN-2-ONE) -N 4-(6-METHOXY-8-QUINOLINYL)-1,4-PENTANEDIAMINE AS GAMETOCYTOCIDAL AGENT QDPR, NQO2, G6PD HSP90AA1 3530/4885HSP90AB1 4111/4885IDO1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.